Last reviewed · How we verify
DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE
DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE is a drug developed by AUROBINDO PHARMA USA. It is currently FDA-approved.
At a glance
| Generic name | DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE |
|---|---|
| Sponsor | AUROBINDO PHARMA USA |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Booster-free Antiretroviral Therapy for Persons Living With HIV and Multidrug Resistance: A Multicentre Multi-stage Randomized Trial (Phase 4)
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravi (Phase 3)
- Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum (N/A)
- A Phase 3b, Multicenter, Single-arm, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to DTG/3TC Single Tablet Regimen Administered Once Daily From a Bictegravir/Emtrici (Phase 3)
- A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral T (Phase 3)
- A Pilot Study of Rapid HIV Treatment Initiation, Access and Engagement in Care (RHAE) (NA)
- An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic (Phase 4)
- Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Ala (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE CI brief — competitive landscape report
- DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE updates RSS · CI watch RSS
- AUROBINDO PHARMA USA portfolio CI
Frequently asked questions about DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE
What is DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE?
DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE is a pharmaceutical drug developed by AUROBINDO PHARMA USA.
Who makes DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE?
DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE is developed and marketed by AUROBINDO PHARMA USA (see full AUROBINDO PHARMA USA pipeline at /company/aurobindo-pharma-usa).
What development phase is DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE in?
DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE is FDA-approved (marketed).
Related
- Manufacturer: AUROBINDO PHARMA USA — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing